Neurotensin: an endogenous psychostimulant?

[1]  V. Pickel,et al.  High‐affinity neurotensin receptors in the rat nucleus accumbens: Subcellular targeting and relation to endogenous ligand , 2001, The Journal of comparative neurology.

[2]  A. Bérod,et al.  Neurons of origin of the neurotensinergic plexus enmeshing the ventral tegmental area in rat: retrograde labeling and in situ hybridization combined , 2001, Neuroscience.

[3]  K. Keefe,et al.  Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum , 2001, Neuroscience.

[4]  D. Accili,et al.  Neurotensin Gene Expression and Behavioral Responses Following Administration of Psychostimulants and Antipsychotic Drugs in Dopamine D3 Receptor Deficient Mice , 2001, Neuropsychopharmacology.

[5]  T. Tzschentke.  Pharmacology and behavioral pharmacology of the mesocortical dopamine system , 2001, Progress in Neurobiology.

[6]  K. Fuxe,et al.  Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain , 2001, Neuroscience.

[7]  E. Richelson,et al.  Neurotensin: peptide for the next millennium , 2000, Regulatory Peptides.

[8]  P. Rompré,et al.  Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing , 2000, Brain Research.

[9]  P. Rompré,et al.  Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization , 2000, Neuropharmacology.

[10]  P. Kalivas,et al.  Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies , 2000, Psychopharmacology.

[11]  Christian Broberger,et al.  Neuropeptides — an overview , 2000, Neuropharmacology.

[12]  P. Soubrié,et al.  Comparative effects of neurotensin, neurotensin(8-13) and [D-Tyr11]neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens , 2000, Neuroscience.

[13]  L. Trudeau.  Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors , 2000, Neuroscience.

[14]  Marc Laruelle,et al.  The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies , 2000, Brain Research Reviews.

[15]  A. Beaudet,et al.  Pharmacological, molecular and functional characterization of glial neurotensin receptors , 1999, Neuroscience.

[16]  C. Nemeroff,et al.  Does neurotensin mediate the effects of antipsychotic drugs? , 1999, Biological Psychiatry.

[17]  J P Vincent,et al.  Neurotensin and neurotensin receptors. , 1999, Trends in pharmacological sciences.

[18]  M. Laburthe,et al.  Neurotensin and a non‐peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice , 1999, International journal of cancer.

[19]  J. Krause,et al.  Distinct and interactive effects of d‐amphetamine and haloperidol on levels of neurotensin and its mRNA in subterritories in the dorsal and ventral striatum of the rat , 1998, The Journal of comparative neurology.

[20]  W. Rostène,et al.  Role of Endogenous Neurotensin in the Behavioral and Neuroendocrine Effects of Cocaine , 1998, Neuropsychopharmacology.

[21]  R. Spanagel,et al.  Repeated Administration of the Neurotensin Receptor Antagonist SR 48692 Differentially Regulates Mesocortical and Mesolimbic Dopaminergic Systems , 1998, Journal of neurochemistry.

[22]  W. Rostène,et al.  Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. , 1997, Trends in pharmacological sciences.

[23]  Jeffrey A Lieberman,et al.  Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.

[24]  R. Christopher Pierce,et al.  A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants , 1997, Brain Research Reviews.

[25]  P. Rompré.  Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine. , 1997, European journal of pharmacology.

[26]  P. Soubrié,et al.  Involvement of cortical neurotensin in the regulation of rat meso‐cortico‐limbic dopamine neurons: Evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade , 1997, Synapse.

[27]  W. Rostène,et al.  Neurotensin and Neuroendocrine Regulation , 1997, Frontiers in Neuroendocrinology.

[28]  W. Rostène,et al.  Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum. , 1997, Brain research. Molecular brain research.

[29]  P. Soubrié,et al.  Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. , 1997, The Journal of pharmacology and experimental therapeutics.

[30]  Anthony A. Grace,et al.  Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs , 1997, Trends in Neurosciences.

[31]  J. S. Brog,et al.  Morphologically distinct subpopulations of neurotensin-immunoreactive striatal neurons observed in rat following dopamine depletions and D2 receptor blockade project to the globus pallidus , 1996, Neuroscience.

[32]  G. Hanson,et al.  Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  D. Boulay,et al.  Locomotor sensitization to [d-Trp11]neurotensin after repeated injections of the dopamine uptake inhibitor GBR12783 in rats , 1996, Neuroscience Letters.

[34]  T. Svensson,et al.  Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat , 1995, Behavioural Brain Research.

[35]  R. Roth,et al.  Preexposure to, but Not Cotreatment with, the Neurotensin Antagonist SR 48692 Delays the Development of Cocaine Sensitization , 1994, Neuropsychopharmacology.

[36]  M. Martres,et al.  Opposing Roles for Dopamine D2 and D3 Receptors on Neurotensin mRNA Expression in Nucleus Accumbens , 1994, The European journal of neuroscience.

[37]  S. Gygi,et al.  Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. , 1994, The Journal of pharmacology and experimental therapeutics.

[38]  P. Soubrié,et al.  SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission , 1994, Neuroscience.

[39]  P. Robledo,et al.  Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat , 1993, Brain Research.

[40]  P. Rompré,et al.  Mesencephalic microinjections of neurotensin-(1–13) and its C-terminal fragment, neurotensin-(8–13), potentiate brain stimulation reward , 1993, Brain Research.

[41]  R. Roth,et al.  Effects of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex , 1992, Neuroscience Letters.

[42]  Zhao-jin Wang,et al.  Tyrosine hydroxylase-, neurotensin-, or cholecystokinin-containing neurons in the nucleus tractus solitarii send projection fibers to the nucleus accumbens in the rat , 1992, Brain Research.

[43]  P. Rompré,et al.  Facilitation of brain stimulation reward by mesencephalic injections of neurotensin-(1-13). , 1992, European journal of pharmacology.

[44]  P. Duffy,et al.  Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  J. Crawley,et al.  Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens , 1990, Brain Research.

[46]  P. Glimcher,et al.  Neurotensin self-injection in the ventral tegmental area , 1987, Brain Research.

[47]  C. Nemeroff,et al.  Repeated neurotensin administration in the ventral tegmental area: Effects on baseline and d-amphetamine-induced locomotor activity , 1986, Neuroscience Letters.

[48]  P. Kalivas,et al.  Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens , 1984, Brain Research.

[49]  P. Glimcher,et al.  Neurotensin: A new ‘reward peptide’ , 1984, Brain Research.

[50]  P. Kalivas,et al.  Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat , 1983, Neuroscience.

[51]  P. Kalivas,et al.  Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin. , 1982, European journal of pharmacology.

[52]  C. Nemeroff,et al.  Neurotensin blocks certain amphetamine-induced behaviours , 1981, Nature.

[53]  K. Berridge,et al.  Incentive-sensitization and addiction. , 2001, Addiction.

[54]  P. Soubrié,et al.  Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons. , 2000, Neuroreport.

[55]  P. Soubrié,et al.  Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Nemeroff.  Neurotensin: perchance an endogenous neuroleptic? , 1980, Biological psychiatry.